Recombinant Vesicular Stomatitis Virus-Expressing Interferon-Beta And Tyrosinase Related Protein 1
Metastatic Melanoma
Mayo Clinicgene_therapyPhase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 73/ 100
Competitive context
87 Active assets in the Metastatic Melanoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DACARBAZINE Shanghai Junshi Bioscience Co., Ltd. | Phase 4 | BBB |
Nivolumab Bristol-Myers Squibb | Phase 4 | BB |
TIL East Metropolitan Health Service, Australia | Phase 2 | BB |
Ipilimumab NYU Langone Health | Phase 4 | BB |
Irinotecan Melanoma and Skin Cancer Trials Limited | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Recombinant Vesicular Stomatitis Virus-Expressing Interferon-Beta And Tyrosinase Related Protein 1 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →